Cartesian Therapeutics Inc

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Topline data from Phase 2b trial of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis on track for mid-2024

Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

The mean of analysts' price targets for Cartesian Therapeutics, Inc. (RNAC) points to a 146.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade

GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that recently reported twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis will be featured during an oral presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting being held May 7-11, 2024.

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting

Cartesian Therapeutics, Inc. (RNAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)

GAITHERSBURG, Md.--(BUSINESS WIRE)--Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 3:00 p.m. ET. A live webcast of the fireside chat is expected to be accessible in the Events section of the Company's website at www.cartesianthe.

Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Proposals approved at Company's special meeting of stockholders held March 27, 2024 Proposals approved at Company's special meeting of stockholders held March 27, 2024

Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split

Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) remains on track for mid-2024

Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

GAITHERSBURG, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March:

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

New facility expected to support expanded cGMP manufacturing of clinical and commercial supply of Company's pipeline of mRNA cell therapies for the treatment of autoimmune diseases

Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland

Cartesian Therapeutics (NASDAQ: RNAC ) stock is falling on Monday after the clinical-stage biopharmaceutical company revealed a delisting notice. This notice comes from the Nasdaq Listing Qualifications department and has to do with the price of RNAC stock.

Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?

PHILADELPHIA , Jan. 18, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Cartesian Therapeutics, Inc. (NASDAQ: RNAC) ("Cartesian"), formerly known as Selecta Biosciences, Inc. (SELB), on behalf of the company's investors. Since February 2023, shares of Cartesian's common stock have declined in value from a trading price of over $1.75 per share to a current trading price of less than $1.00 per share, a cumulative decline of over 42% in value.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) and Encourages Investors to Contact the Firm

News for Cartesian Therapeutics Inc Stock (RNAC)